Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Roche receives new EU approval for Avastin in cervical cancer

Roche receives new EU approval for Avastin in cervical cancer

9th April 2015

Roche has announced that its drug Avastin has been approved in Europe for a new advanced cervical cancer indication.

The European Commission has approved Avastin in combination with standard chemotherapy for the treatment of adult patients with persistent, recurrent or metastatic carcinoma of the cervix.

This approval was based on the significant survival benefit demonstrated by the therapy in the pivotal GOG-0240 study. Women who received Avastin plus chemotherapy saw a 26 percent reduction in the risk of death compared to those on chemotherapy alone, representing a median improvement in survival of nearly four months.

Currently, fewer than one in six women with this disease are alive five years after diagnosis. Avastin is the first treatment in nearly a decade to extend the life of women with advanced cervical cancer.

Dr Sandra Horning, chief medical officer and head of global product development at Roche, said: "We are pleased that women in Europe now have a much-needed new treatment option that is proven to help them live longer lives compared to chemotherapy alone."

More than 1.5 million patients have been treated with Avastin to date. It was approved for the treatment of platinum-resistant recurrent ovarian cancer in Europe last year.ADNFCR-8000103-ID-801782901-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.